Therapeutic agents for targeting desmoplasia: current status and emerging trends

Simple item page
dc.contributor.authorChitkara, Deepak
dc.contributor.authorMittal, Anupama
dc.date.accessioned2024-01-05T06:51:25Z
dc.date.available2024-01-05T06:51:25Z
dc.date.issued2020-11
dc.description.abstractDesmoplasia is a major barrier to chemotherapy in several cancers, particularly pancreatic ductal adenocarcinoma and breast cancer. Tumors comprise of cellular and noncellular components and chemoresistant cancer stem cells (CSCs) with established signaling pathways. In this review, we discuss drugs, such as pentoxifylline, aspirin, and metformin, that have been repurposed and investigated for their antidesmoplastic activity in combination with antitumor drugs. We also highlight less explored new small-molecule drugs, and gene and peptide-based therapeutics for the treatment of desmoplasia and to target CSCs. Promising results from preclinical studies have encouraged several clinical trials to evaluate these antidesmoplastic agents as adjunct to chemotherapy.en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1359644620303652
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13677
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectPharmacyen_US
dc.subjectTherapeutic agentsen_US
dc.subjectDesmoplasiaen_US
dc.subjectCancer stem cells (CSCs)en_US
dc.subjectChemotherapyen_US
dc.titleTherapeutic agents for targeting desmoplasia: current status and emerging trendsen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Department of Pharmacy